SL-145 is a novel C-terminal HSP90 inhibitor, induces apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling.
SL-145 targets the C-terminal domain of HSP90, does not trigger the heat shock response (HSR), compared to other inhibitors.
SL-145 markedly downregulated AKT, MEK, and ERK expression and reduced their phosphorylation.
SL-145 impedes tumor growth by targeting breast cancer stem cell (BCSC)-like properties in vitro and in vivo, impairs metastatic spread from primary tumors via dysregulation of STAT3 signaling.
